

**FRAZER MEDICAL RESEARCH LIMITED  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023**

**Frazer Medical Research Limited**  
**Unaudited Financial Statements**  
**For The Year Ended 31 March 2023**

---

**Contents**

	<b>Page</b>
Balance Sheet	1–2
Notes to the Financial Statements	3–5

**Frazer Medical Research Limited**  
**Balance Sheet**  
**As At 31 March 2023**

Registered number: 02611177

		<b>2023</b>		<b>2022</b>	
	<b>Notes</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>FIXED ASSETS</b>					
Tangible Assets	<b>3</b>		71,494		87,258
Investments	<b>4</b>		49,737		49,737
			<u>121,231</u>		<u>136,995</u>
<b>CURRENT ASSETS</b>					
Debtors	<b>5</b>	50,417		24,705	
Cash at bank and in hand		95,670		23,300	
		<u>146,087</u>		<u>48,005</u>	
<b>Creditors: Amounts Falling Due Within One Year</b>	<b>6</b>	(87,952 )		(42,460 )	
			<u>58,135</u>		<u>5,545</u>
<b>NET CURRENT ASSETS (LIABILITIES)</b>					
			<u>179,366</u>		<u>142,540</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
			<u>179,366</u>		<u>142,540</u>
<b>NET ASSETS</b>					
<b>CAPITAL AND RESERVES</b>					
Called up share capital	<b>7</b>		100		100
Profit and Loss Account			179,266		142,440
			<u>179,366</u>		<u>142,540</u>
<b>SHAREHOLDERS' FUNDS</b>			<u>179,366</u>		<u>142,540</u>

**Frazer Medical Research Limited**  
**Balance Sheet (continued)**  
**As At 31 March 2023**

---

For the year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

-----  
Dr John Frazer

Director

21/12/2023

The notes on pages 3 to 5 form part of these financial statements.

**Frazer Medical Research Limited**  
**Notes to the Financial Statements**  
**For The Year Ended 31 March 2023**

---

**1. Accounting Policies**

**1.1. Basis of Preparation of Financial Statements**

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

**1.2. Turnover**

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

**Sale of goods**

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

**Rendering of services**

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

**1.3. Tangible Fixed Assets and Depreciation**

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold	on Director's valuations
Plant & Machinery	15% reducing balance
Motor Vehicles	25% reducing balance
Fixtures & Fittings	15% reducing balance
Computer Equipment	30% reducing balance

**1.4. Taxation**

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

**2. Average Number of Employees**

Average number of employees, including directors, during the year was: 2 (2022: 2)

**Frazer Medical Research Limited**  
**Notes to the Financial Statements (continued)**  
**For The Year Ended 31 March 2023**

**3. Tangible Assets**

	<b>Land &amp; Property</b>			
	<b>Freehold</b>	<b>Plant &amp; Machinery</b>	<b>Motor Vehicles</b>	<b>Fixtures &amp; Fittings</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Cost</b>				
As at 1 April 2022	8,000	92,328	43,199	23,158
As at 31 March 2023	8,000	92,328	43,199	23,158
<b>Depreciation</b>				
As at 1 April 2022	-	53,700	4,500	21,263
Provided during the period	-	5,794	9,675	284
As at 31 March 2023	-	59,494	14,175	21,547
<b>Net Book Value</b>				
As at 31 March 2023	8,000	32,834	29,024	1,611
As at 1 April 2022	8,000	38,628	38,699	1,895

	<b>Computer Equipment</b>	<b>Total</b>
	<b>£</b>	<b>£</b>
<b>Cost</b>		
As at 1 April 2022	2,394	169,079
As at 31 March 2023	2,394	169,079
<b>Depreciation</b>		
As at 1 April 2022	2,358	81,821
Provided during the period	11	15,764
As at 31 March 2023	2,369	97,585
<b>Net Book Value</b>		
As at 31 March 2023	25	71,494
As at 1 April 2022	36	87,258

**4. Investments**

	<b>Listed £</b>
<b>Cost</b>	
As at 1 April 2022	49,737
As at 31 March 2023	49,737
<b>Provision</b>	
As at 1 April 2022	-
As at 31 March 2023	-
<b>Net Book Value</b>	
As at 31 March 2023	49,737
As at 1 April 2022	49,737

**Frazer Medical Research Limited**  
**Notes to the Financial Statements (continued)**  
**For The Year Ended 31 March 2023**

**5. Debtors**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
<b>Due within one year</b>		
Trade debtors	36,673	10,961
Prepayments and accrued income	3,744	3,744
Other debtors	10,000	10,000
	<u>50,417</u>	<u>24,705</u>

**6. Creditors: Amounts Falling Due Within One Year**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Bank loans and overdrafts	-	18,497
Corporation tax	15,579	15,046
Other taxes and social security	1,261	718
VAT	7,813	4,847
Accruals and deferred income	3,000	3,000
Directors' loan accounts	60,299	352
	<u>87,952</u>	<u>42,460</u>

**7. Share Capital**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Allotted, Called up and fully paid	<u>100</u>	<u>100</u>

**8. General Information**

Frazer Medical Research Limited is a private company, limited by shares, incorporated in England & Wales, registered number 02611177 . The registered office is Hazeldene 32 Hall Drive, Bramhope, Leeds, West Yorkshire, LS16 9JE.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.